Patel Anish's Form 4 filing
Enliven Therapeutics, Inc. (ELVN) · filed Jan 2, 2024
- Accession no.
- 0001209191-24-000256
- Filed
- Jan 2, 2024
- Trade date
- Dec 28, 2023-Jan 2, 2024
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions. Open-market sales total $203.3K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Patel AnishCIK 0001967163 | Officer (Chief Operating Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 28, 2023 | Common Stock | SSaleDisposed | −2,520 | $15.08F2 | −$38,001.6 | 33,117 | Direct | |
| Dec 29, 2023 | Common Stock | SSaleDisposed | −20 | $15.00 | −$300 | 33,097 | Direct | |
| Jan 2, 2024 | Common Stock | SSaleDisposed | −11,000 | $15.00F3 | −$165,000 | 22,097 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $15.00 to $15.28. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F3
This transaction was executed in multiple trades at prices ranging from $15.00 to $15.005. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.